ASM Attends UN General AssemblyASM President, Susan Sharp, Ph.D., joined global leaders at the United Nations General Assembly in New York today in a historical meeting to focus on the commitment to fight AMR.
Fernando Baquero, M.D., Ph.D., has been named laureate of the Aventis Pharmaceuticals Award, ASM's premier award in antimicrobial chemotherapy. Established in 1982, the Aventis Pharmaceuticals Award honors sustained accomplishment in research toward the development of new antimicrobial agents, the investigation of action or resistance, and the pharmacology, toxicology, or clinical use of those agents.
Recognized around the world as a leading clinical microbiologist and a pioneer in the study of infectious diseases in his native Spain, Baquero has made remarkable contributions to research in antimicrobial chemotherapy and resistance. He will present the Aventis Pharmaceuticals Award Lecture, "Microbial Evolution Under the Influence of Human Chemotherapy," at the upcoming 42nd annual ICAAC in San Diego, Calif.
Baquero has maintained "continuous fun and excitement around microbiology and chemotherapy," and says science is his "permanent fountain of youth and joy." During a career characterized by first-rate patient care and diagnostics, extensive professional service, and exemplary teaching and training of other physicians, he has done significant research in a broad range of areas. Highlights of work by Baquero and colleagues include the discovery of microcins, their differentiation from colicins, and the description of the genetic basis for the production of microcins in Enterobacteriaceae. His group made the first demonstration of plasmids in Listeria species, defined efflux mechanisms of antimicrobial resistance in Listeria, and participated in the Listeria genome project. He is credited with the first documentation of inducible/constitutive macrolide-lincosamide resistance in Bacteroides and Peptostreptococcus-and the recent first description of beta-lactamase in anaerobic cocci.
Baquero has likewise advanced the study of the origin, evolution, and epidemiology of beta-lactamases, especially ESBLs and IRTs in members of the family Enterobacteriaceae. His elegant studies on hypermutable clinical strains of Streptococcus pneumoniae and Pseudomonas aeruginosa have shown that hypermutators are more resistant to antimicrobials and can survive in certain patients, like those with cystic fibrosis, for decades. He has also evaluated several new antimicrobial agents and been a leader in the movements to find a common basis for antimicrobial susceptibility testing and to promote responsible use of antimicrobials in Europe.
His many contributions have taken place in a unique and challenging historical context, in a Spain that he describes as "scientifically devastated" after the Civil War in the 1930s. Baquero notes, "We started very late, but have put forth enormous efforts to make rapid progress." He has been a leader of those efforts, and founded (in 1970) one of the first independent clinical microbiology units in Spain, the Section of Clinical Microbiology at Children's Hospital in Madrid. He is also founder and former director of the Department of Microbiology at Ramon y Cajal Hospital, Madrid.
Fernando Baquero earned his M.D. at Complutensis University School of Medicine in Madrid in 1965 and continued his training in microbiology and infectious diseases in Spain and Germany. He received a Ph.D. from the Autonomous University in Madrid in 1973. He is currently scientific secretary of the Spanish Society for Clinical Microbiology and president of its Clinical Microbiology Group. He is a member of the ASM News editorial board and past member of the ICAAC Program Committee. A Fellow of the American Academy of Microbiology (AAM), Baquero was nominated for the Aventis Award by AAM Fellow Robert Moellering.
The 2002 Merck Irving S. Sigal Memorial Award laureates are Cesar Augusto Arias, M.D., Ph.D., and Laurent Poirel, Ph.D. Proudly sponsored by Merck Worldwide Human Health, the Sigal Awards reward young investigators residing outside North America for excellence and promise in microbiology and infectious disease research. The awards are given in memory of Dr. Irving S. Sigal, a physician-scientist instrumental in the development of the HIV/AIDS drug indinivar sulfate, or CRIXIVAN.
Arias is Assistant Professor of Medicine and Head, Bacterial Molecular Genetics Unit, Universidad El Bosque School of Medicine, Santafe, Bogotá, Colombia. A practicing physician and consultant in clinical microbiology who finished his M.D. at the Universidad El Bosque in 1992, Arias earned his M.Sc. in clinical microbiology at the University of London and his Ph.D. in molecular biology and microbial biochemistry at the University of Cambridge, United Kingdom, in 2000. He is recognized for work on resistance to glycopeptide antibiotics.
While a Ph.D. candidate at Cambridge with Peter E. Reynolds, Arias deciphered the molecular bases of the Van C resistance phenotype, specifying resistance to vancomycin family antibiotics in Enterococcus gallinarum. He worked out the underlying enzymology to prove that d-serine was provided by a novel serine racemase encoded by the vanT gene in the resistance cluster. Next, Arias was able to characterize the other genes and proteins in the resistance cluster, finally providing a coherent picture of evolution of resistance and mode of action in this phenotype.
Arias is a recipient of the Wellcome Trust International Development Award and the Sebastian Bago Award of the International Society for Infectious Diseases. He was nominated for the Sigal Award by Patrice Courvalin, a past laureate of the Aventis Pharmaceuticals Award and a Fellow of the American Academy of Microbiology (AAM).
A graduate of the University of Paris XI, France, and a past laureate of the Young Investigator Award of the French Society of Microbiology, Laurent Poirel earned his Ph.D. in medical virology at the Hôpital Pitié-Salpêtrière in 1998. There, his research focused on the molecular characterization, epidemiology, and pathogenicity of the novel human herpesviruses. He demonstrated the high prevalence in the general population of HHV-6 and HHV-7 and the intrauterine transmission of HHV-6. He later explicated the involvement of HHV-8 in Kaposi's sarcoma and Castleman's disease.
He began postdoctoral work in the research unit of Patrice Nordmann (Molecular Mechanisms of Antibiotic Resistance in gram-negatives) at the Bicêtre Hospital, South-Paris Medical School, in 1998. He has since produced findings on the genetic bases of natural and acquired resistance to β-lactams in gram-negative rods that have important implications for the resolution of difficult therapeutic problems.
Poirel has identified and characterized novel and clinically relevant β-lactamase-mediated resistance mechanisms in Enterobacteriaceae and Pseudomonas aeruginosa, including integron-mediated extended-spectrum β-lactamases like VEB-1, highly prevalent among Southeast Asian isolates. He also identified and characterized the metallo-carbapenamase VIM-2 in Pseudomonas aeruginosa, now reported worldwide, and a point-mutant derivative of an extended-spectrum β-lactamase whose hydrolysis spectrum is extended to carbapenems.
The ICAAC Young Investigator Awards, sponsored by Merck U.S. Human Health since 1983, were established to encourage and reward young investigators residing in North America for scientific promise and demonstrated excellence in microbiology and infectious disease research. David R. Andes, M.D., and Marc Lipsitch, D.Phil., are the 2002 award laureates.
Andes is honored as a true leader in the evaluation of proper dosage of antiinfectives, an increasingly important area of infectious disease research given the emergence and spread of resistant organisms. He has used a disseminated Candida model in neutropenic mice to study important antifungal drugs including fluconazole, flucytosine, amphotericin B, and ravuconazole. His experimental designs have featured dose fractionation at several different total doses, thereby reducing interdependence among various pharmacokinetic/pharmacodynamic (PK/PD) parameters. His innovative research is helping to define the PK/PD parameters best correlated with in vivo efficacy and determine the magnitude of PK/PD parameters required for positive outcomes.
Currently an assistant professor in the Division of Infectious Diseases at the University of Wisconsin Medical School, Madison, Andes serves as the institution's principal investigator for the renowned NIH Mycology Study Group. A graduate of St. Louis University, he earned his M.D. at the University of Missouri Medical School in Columbia. He completed his residency in infectious diseases at Wisconsin and was Chief Medical Resident in 1995-96. He continued at Wisconsin with clinical and research fellowship training from 1996-1999. William A. Craig, past chair of the ICAAC Program Committee and a Fellow of the American Academy of Microbiology (AAM), nominated David Andes for the ICAAC Young Investigator Award.
Marc Lipsitch, Assistant Professor of Epidemiology, Harvard School of Public Health, Boston, Mass., is honored for achievement in both theoretical and experimental research. His studies of the population dynamics of antimicrobial chemotherapy in individual patients, open communities, and hospitals have increased the understanding of the processes responsible for the evolution and persistence of resistant bacteria. One of the first scientists to provide theoretical and analytical background for evaluating the effects of different antibiotic policies, he has provided mathematical models to explain the observation that changes in prescribing practices decrease the risk of colonization with resistant bacteria at large, but increase risk for individual patients. He has likewise produced important findings on the evolutionary implications of viruses transmitted by the horizontal and vertical route and on the effects of vaccination and antimicrobial treatment on the population biology of Streptococcus pneumoniae.
A Rhodes Scholar at Oxford University, United Kingdom from 1992-1995, Lipsitch earned his D.Phil. in zoology following a B.A. in philosophy from Yale University, New Haven, Conn. He went on to do postdoctoral work with his nominator for this award, AAM Fellow Bruce R. Levin, at Emory University in Atlanta, Ga. While training in Atlanta, he served as a visiting scientist at the Centers for Disease Control and Prevention from 1997-1999.
ASM Journals in National Library of Medicine Pilot Project
ASM journals have been selected for a National Library of Medicine (NLM) pilot project, begun in the spring of this year, to produce a digital archive of life science journals back as far as available. This archive will provide the public with easy, online access to a broad spectrum of full-text PDF articles and develop increased chances of long-term preservation.
NLM intends to scan a small subset of Medline journals that are participating in PubMed Central, including ASM's journals. PubMed Central is a digital archive of life science journal literature managed by the National Center for Biotechnology Information (NCBI) at NLM.
Each journal will be scanned, cover to cover, from its earliest available date of publication forward to issues currently deposited in PubMed Central. OCR text of sufficient quality to build indexes for full-text searching and to use for other background processing will be generated automatically from the scanned images.
ASM will provide copies of its available print issues to be used for scanning and will receive copies of the scanned page images and corresponding text files for its own use. Scanned articles will be freely available in PubMed Central as PDF files. Citations and abstracts for the articles will be included in NLM's bibliographic citation database, PubMed. Other journals identified for participation in this project include the Journal of the Medical Library Association, Molecular Biology of the Cell, and Nucleic Acids Research. As with existing content in PubMed Central, copyright for publishers' scanned material will remain with the publishers or with individual authors, as applicable.
2002 Corporate Activities Program (CAP)
From the Greek, meaning, "love for mankind," philanthropy is an altruistic concern for human welfare and advancement through donations. The concept of modern voluntary giving includes the granting of money to nonprofit organizations by foundations and corporations to promote the common good and improve the quality of life. The generosity of the Corporate Activities Program (CAP) Partners and Sponsors provides ASM with the funds needed to supply travel grants to postdoctoral fellows and undergraduate and graduate students to either ICAAC or the General Meeting.
The charitable support of CAP members helps insure the continuation of education and research in the microbiological sciences. Please show your appreciation of this support to the 18 members of the 2002 Corporate Activities Program by visiting their websites or the corporate booths of those participating in the 42nd ICAAC exhibits. CAP corporations are identified in various ASM publications by the CAP logo (the ASM microscope and the year of CAP participation) and CAP lapel pins are provided to ASM's principal corporate colleagues.
There are two levels of participation: Corporate Partner, the higher level, and Corporate Sponsor.
Corporate Partners (as of 15 July 2002)
AstraZeneca Pharmaceuticals LP
1800 Concord Pike
Wilmington, DE 19850
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture, and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world, with health care sales of $15.8 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS), and respiratory products. AstraZeneca develops and markets a range of products, including those designed to treat and prevent serious infection-a major healthcare problem worldwide. We provide innovative, effective medicines that make a real difference for patients in important areas of healthcare. (AstraZeneca Pharmaceuticals LP is exhibiting at ICAAC in booth 913.)
BD Diagnostic Systems
7 Loveton Circle
Sparks, MD 21152
BD Diagnostic Systems serves clinical, industrial, research, and physician office laboratories around the world with solutions for disease diagnosis, blood banking, and physician office laboratory testing. BD is the market leader in microbiology with innovative new products in areas such as molecular diagnostics, tuberculosis testing, and microbial identification. BD offers products ranging from culture media to DNA probe assays used in clinical and physician office laboratories, biopharmaceutical fermentation media used in industrial settings, and many more products that enhance diagnostic and industrial processes. BD is dedicated to achieving cost-effective solutions by providing real time diagnostic testing in hospitals and physician offices. (BD Diagnostic Systems is exhibiting at ICAAC in booth 520 and is the sponsor of the General Meeting registration bags.)
Bristol-Myers Squibb Company
7777 Scudders Mill Road
Plainsboro, NJ 08536
Bristol-Myers Squibb is a leading diversified worldwide health and personal care company whose principal businesses are medicines, beauty care, nutritionals, and medical devices. Our mission is to extend and enhance human life by providing the highest-quality health and personal care products. (Bristol-Myers Squibb Company is exhibiting at ICAAC in booth 1412.)
1250 S. Collegeville Road
Collegeville, PA 19426
GlaxoSmithKline (GSK) is a world-leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing health care environment. GSK's mission is to improve the quality of human life by enabling people to do more, feel better, and live longer. Headquartered in the United Kingdom and with operations based in the United States, the new company is one of the industry leaders, with an estimated 7% of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas: antiinfectives, central nervous system (CNS), respiratory, and gastrointestinal/metabolic. In addition, GSK is a leader in the important area of vaccines and has a growing portfolio of oncology products. (GlaxoSmithKline Pharmaceuticals is exhibiting at ICAAC in booth 2008.)
Lilly Corporate Center
Indianapolis, IN 46285
Lilly is a leading innovation-driven pharmaceutical corporation developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from worldwide laboratories and collaborations with eminent scientific organizations. Lilly is identifying high-potential drug candidates by improving the research and development processes, investing in new research technologies, and expanding research teams.
2000 Galloping Hill Road
Kenilworth, NJ 07033
Schering-Plough is a research-based company headquartered in the United States engaged in the discovery, development, manufacturing, and marketing of pharmaceuticals and health care products worldwide. The company's central strategic objective is the discovery and development of novel therapeutics that can improve people's health and extend lives. Schering-Plough's antiinfective and anticancer product category comprises a number of the company's most important therapies. From products that treat specific types of cancer to products for hepatitis C, our focused research and development activities in this area have enabled Schering-Plough to discover and develop new treatments for various cancers and chronic infections. (Schering Oncology/Biotech is exhibiting at ICAAC in booth 1438.)
The Procter & Gamble Company
One Procter & Gamble Plaza
Cininnati, OH 45202
Proctor and Gamble's core values and principles drive our purpose of providing products and services of superior quality and value to improve the lives of the world's consumers.
34790 Ardentech Court
Fremont, CA 94555
Versicor, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing novel, broad-spectrum antifungal and antibiotic agents with distinct competitive advantages. Its lead products, a novel antifungal agent and a novel antibiotic for the treatment of serious gram-positive infections, are in the advanced stages of clinical development. The company's versatile research engine integrates industry-leading expertise in functional genomics, automated screening and combinatorial and medicinal chemistry. In addition, Versicor has extensive research and development collaborations with leading pharmaceutical and anti-infective development companies. (Versicor, Inc. is exhibiting at ICAAC in booth 612.)
150 Radnor Chester Road
St. Davids, PA 19087
Wyeth is committed to helping people throughout the world lead healthier lives through advances in health care. We are proud of the vaccines, medications, and nutritional products that we research and develop and on quality manufacturing; responsible sales, marketing, and licensing alliances; commitment to educational programs and initiatives; and service to health care professionals and patients. (Wyeth Pharmaceuticals is exhibiting at ICAAC in booth 2228 and 2428 and is the sponsor of the Annual History of Microbiology Lecture.)
Corporate Sponsors (as of 15 July 2002)
300 Somerset Corporate Boulevard
Bridgewater, NJ 08807-2854
Aventis is an established global leader in the field of health care. You can easily obtain answers to health-related questions, conduct your own research, and come in direct contact with competent professionals through www.Aventis.com. (Aventis Pharmaceuticals is exhibiting at ICAAC in booth 718 and 828.)
Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015
Baxter International Inc. is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's bioscience, medication delivery, and renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease, and trauma. With approximately 48,000 team members in 110 countries, Baxter is a global leader in developing innovative medical therapies that improve the quality of life for people around the world.
400 Morgan Lane
West Haven, CT 06516
Research may start in a laboratory, but it ends with an individual-a living, breathing person. For more than 100 years, the Bayer Pharmaceutical division's high-quality drug products have helped patients lead healthier lives. Bayer researchers seek innovative treatments for diseases. Furthermore, Bayer's financial commitment to research has increased its productivity more than 400% since 1997, putting Bayer that much closer to the therapies and cures of the future. Bayer is committed to providing ethical products to treat infections, hypertension and angina, a blood conservation agent for patients undergoing coronary artery surgery, and type 2 diabetes. Bayer scientists work with state-of-the-art technology in facilities located in the world's research and development epicenters. This means access not only to the best equipment, but also to the best minds in the pharmaceuticals field. This translates into a pipeline of innovative therapies that are rapidly maturing. Now, better drugs can be available faster. (Bayer Corporation is exhibiting at ICAAC in booth 1728 and is the sponsor of the ICAAC Meeting Portfolios.)
100 Roldophe Avenue
Durham, NC 27712
As a major in vitro diagnostics company focusing on infectious diseases, bioMeriéux develops, manufactures, and markets reagents and automated systems designed for medical analyses and product quality control in the agri-food, cosmetics, and pharmaceutical industries, and the environment. Our mission is to maintain a front-line position in the worldwide struggle against infectious diseases in clinical and industrial biology. To achieve this, we have developed a strategy that involves innovations in microbiology, immunoassays, and molecular diagnostics, strengthening our worldwide network and improving our operational profitability to free the resources needed to finance our research and international development. (bioMeriéux, Inc. is exhibiting at ICAAC in booth 1212.)
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877
Scientific excellence is one of Boehringer Ingelheim Pharmaceuticals' greatest strengths, and its principal mission is harnessing its human and technological resources to make significant improvements in human health. The company's clinical research organization is shepherding projects promising new medications for stroke, hypertension, arthritis, HIV, and pulmonary disease through clinical testing and regulatory review. In fact, Boehringer Ingelheim Pharmaceuticals anticipates the launch of 15 new products in the U.S. within the next five years, with many more candidates being added to the pipeline. Scientists at the company's state-of-the-art Research & Development facilities in Ridgefield, Conn., are focusing on the discovery and development of new medications that, through the mediation of the body's immunological and inflammatory processes, hold promise for the treatment of cancer, cardiovascular, respiratory and autoimmune diseases, and central nervous system disorders. (Boehringer Ingelheim Pharmaceuticals, Inc. is exhibiting at ICAAC in booth 929.)
Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington, MA 02421
Cubist engineers major advances against serious infections through a rigorous fusion of the most productive science and business technologies. By applying this unique model and focus, Cubist is dedicated to becoming a global leader in the development and commercialization of novel antiinfectives. (Cubist Pharmaceuticals, Inc. is exhibiting at ICAAC in booth 812 and is the sponsor of the ICAAC City Maps.)
Fujisawa Pharmaceutical Company, Limited
Osaka, 532-8514 JAPAN
Fujisawa's corporate philosophy is "Challenging the unknown frontier known as humans and contributing to healthier, more prosperous lives for people around the world." Fujisawa's commitment to R&D is central to the company's mission to provide new, innovative products that contribute to the health and welfare of people all over the world. Fujisawa leads the Japanese pharmaceutical industry in the development of international operations. Through its overseas subsidiaries and licensing agreements, the company is able to offer a broad range of pharmaceutical products worldwide. (Fujisawa Pharmaceutical Co., Ltd. is exhibiting at ICAAC in booth 1828.)
New Brunswick Scientific Company, Incorporated
44 Talmadge Road
Edison, NJ 08818-4005
New Brunswick Scientific provides technology to the life sciences market, enabling the discovery, development, and production of pharmaceuticals and other biologicals. This technology consists of hardware and the technical know-how, training, and support for our customers to convert their ideas into products. New Brunswick Scientific is committed to the design, development, manufacture, and support of the highest-quality equipment for life science research and pilot production. (New Brunswick Scientific Co., Inc. is the General Meeting sponsor of the President's Forum.)
Olympus America, Incorporated
Two Corporate Center Drive
Melville, NY 11747
A world leader in the development and application of sophisticated optical technology, Olympus has created innovative solutions for consumers, health care, and industry for over 80 years. From Japan's first microscope to the world's first Microcassette® recorder, from some of the most popular cameras in history to technology that tests 80% of the North American blood supply, the combination of innovative ideas, advanced technology, and manufacturing know-how has nourished our growth and satisfied customers worldwide since 1919.
For more information on ASM's Corporate Activities Program or its 2002 participants, contact Sherri Sujai in the ASM Industry Relations Unit at 202-942-9252 or e-mail email@example.com.
Council on Undergraduate Research (CUR) National Conference
Larry Aaronson, Utica College of Syracuse University, N.Y., conducted a workshop "Getting Research Societies to Support Research at Predominantly Undergraduate Institutions" at the 9th National Conference of the Council on Undergraduate Research, 19-22 June, at Connecticut College, New London, Conn. Aaronson and two colleagues provided information about working with professional societies to support undergraduate research at national conferences and through summer research experiences. One example presented was ASM's Undergraduate Research Fellowships . Kristen Catlin, ASM's Education Resources Coordinator, represented the BiosciEdNet (BEN) and ASM. She shared information about the BEN collaborative and provided resources about ASM's MicrobeLibrary website . Most of the attendees of the conference were undergraduate faculty members in the sciences. Those teaching in the biological sciences were very receptive to the BEN project, as well as the various fellowships, educational resources, and education conferences sponsored by the ASM Education Board.
ASM Reaches Out to Teachers
On 22 May 2002 during the 102nd ASM General Meeting, 20 Salt Lake City area teachers participated in Teacher Science Day, sponsored by the Committee on Precollege Education. Clifford Houston (Education Board chairperson), Ronald Atlas (president- elect), Elizabeth Sockett (representative from the Society for General Microbiology), and Steve Wagner addressed the teachers. Jared Leadbetter of the California Institute of Technology presented on termite-gut symbionts and their use in the classroom. Working in groups, participants engaged in hands-on, inquiry-based activities using readily available and affordable materials. Teachers worked with ASM members, including Kelli Belden, Mary Ann Bruns, John Fedors, Ed Goebel, Millicent Goldsmith, Nancy Hayes, Marie Panec, Jeff Pommerville, Jackie Reynolds, Liliana Rodriguez, Linda Scotten, Lynn Wagner, Musau WaKabongo, and Nan Waksman Schanbacher. Ninety percent of participants planned to use all or some of the workshop activities in their classrooms.
Martin Dworkin, professor of microbiology at the University of Minnesota, Minneapolis, has been elected chair of the Midwest Council of the American Academy of Arts & Sciences (AAAS) and vice president of the Academy. An authority on myxobacteria, Dworkin received his B.S. from Indiana University, Bloomington, and his Ph.D. from the University of Texas, Austin. The Midwest Council represents and serves over 500 Fellows in the region. Founded in 1780 by John Adams, AAAS sponsors studies, projects, and meetings on a wide range of issues that include international security, social policy, education, and the humanities.
AAAS has also inducted ASM members into the 2002 class of new Fellows. They are: Joan W. Conaway, Gregory A. Petsko, and Sue H. Wickner for the biochemistry and molecular biology section; Howard Gest, Everett P. Greenberg, and Thomas E. Shenk for the cellular and developmental biology, microbiology and immunology section; and Mina J. Bissell, Elliott D. Kieff, Victor Nussenzweig, and Jerold M. Olefsky for the medical sciences, clinical medicine, and public health section.
ASM Branches and Divisions on the Web
The following ASM Branches have established numerous websites